Saurashtra News

Propulsion of Acne Vulgaris Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight

 Breaking News
  • No posts were found

Propulsion of Acne Vulgaris Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight

September 03
13:30 2023
Propulsion of Acne Vulgaris Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight

(Albany, United States) As per DelveInsight’s assessment, globally, the Acne Vulgaris Pipeline constitutes 22+ key companies continuously working towards developing 22+ Acne Vulgaris Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Acne Vulgaris Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Acne Vulgaris NDA approvals (if any), and product development activities comprising the technology, Acne Vulgaris collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Acne Vulgaris Pipeline treatment landscape of the report, click here @ Acne Vulgaris Pipeline Outlook

 

Key Takeaways from the Acne Vulgaris Pipeline Report

  • DelveInsight’s Acne Vulgaris Pipeline analysis depicts a robust space with 22+ active players working to develop 22+ pipeline treatment therapies.
  • The leading companies working in the Acne Vulgaris market include Novan Inc., Bausch Health Americas, Inc., AOBiome LLC, Ascletis Pharmaceuticals, AnaptysBio Inc., Botanix Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Xenon Pharmaceuticals Inc., Origimm Biotechnology, Boston Pharmaceuticals, Kintor Pharma, Dermavant Sciences, Eligo Bioscience, Cassiopea Inc., BioPharmX, Madam Therapeutics, SiSaf, and others.
  • Promising Acne Vulgaris Pipeline Therapies in the various stages of development include S6G5T-3, 50 mg P005672-HCl, Tazarotene, Tazaroc Gel, Trifarotene 0.005 % Topical Cream, AKLIEF®, and others.
  • On May 2023, Novan Inc. announced a study of phase 3 clinical trials for SB204 4%. This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.
  • On August 2023, Teva Pharmaceuticals USA announced a study of phase 3 clinical trials for Trifarotene 0.005 % Topical Cream and AKLIEF®. To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.

 

Acne Vulgaris Overview

Acne vulgaris is an inflammatory disorder of the pilosebaceous unit, which runs a chronic course and it is self-limiting. Acne vulgaris is triggered by Cutibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone (DHEA).

 

For further information, refer to the detailed Acne Vulgaris Unmet Needs, click here for Acne Vulgaris Ongoing Clinical Trial Analysis

 

Acne Vulgaris Emerging Drugs Profile

  • IDP126: Bausch Health Americas Inc.
  • DMT310: Dermata Therapeutics

 

Acne Vulgaris Pipeline Therapeutics Assessment

There are approx. 22+ key companies which are developing the therapies for Acne Vulgaris. The companies which have their Acne vulgaris drug candidates in the most advanced stage, i.e. Phase III include, Bausch Health Americas, Inc.

 

Request a sample and discover the recent advances in Acne Vulgaris Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Acne Vulgaris Segmentation

 

Acne Vulgaris Drugs and Companies

  • S6G5T-3: Sol-Gel Technologies Ltd.
  • 50 mg P005672-HCl: Almirall S.A.
  • Tazarotene: Stiefel, a GSK Company
  • Tazaroc Gel: GlaxoSmithKline

 

Acne Vulgaris Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Acne Vulgaris Therapeutics Market include-

Novan Inc., Bausch Health Americas, Inc., AOBiome LLC, Ascletis Pharmaceuticals, AnaptysBio Inc., Botanix Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Xenon Pharmaceuticals Inc., Origimm Biotechnology, Boston Pharmaceuticals, Kintor Pharma, Dermavant Sciences, Eligo Bioscience, Cassiopea Inc., BioPharmX, Madam Therapeutics, SiSaf, and others.

 

Dive deep into rich insights for drugs for the Acne Vulgaris Pipeline, Click here @ Acne Vulgaris Unmet Needs and Analyst Views

 

Scope of the Acne Vulgaris Pipeline Report

  • Coverage- Global
  • Companies- Novan Inc., Bausch Health Americas, Inc., AOBiome LLC, Ascletis Pharmaceuticals, AnaptysBio Inc., Botanix Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Xenon Pharmaceuticals Inc., Origimm Biotechnology, Boston Pharmaceuticals, Kintor Pharma, Dermavant Sciences, Eligo Bioscience, Cassiopea Inc., BioPharmX, Madam Therapeutics, SiSaf, and others.
  • Therapies- S6G5T-3, 50 mg P005672-HCl, Tazarotene, Tazaroc Gel, Trifarotene 0.005 % Topical Cream, AKLIEF®, and others.
  • Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Acne Vulgaris Merger and acquisitions, Licensing Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Acne vulgaris: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. IDP126: Bausch Health Americas, Inc.
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. DMT310: Dermata Therapeutics
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. ORG101: Origimm Biotechnology
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Acne vulgaris Key Companies
  17. Acne vulgaris Key Products
  18. Acne vulgaris- Unmet Needs
  19. Acne vulgaris- Market Drivers and Barriers
  20. Acne vulgaris- Future Perspectives and Conclusion
  21. Acne vulgaris Analyst Views
  22. Acne vulgaris Key Companies
  23. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services